ArticleAlzheimer's & dementia (New York, N. Y.)2020
Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment.
Article in Alzheimer's & dementia (New York, N. Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Return of individual research results from genomic research: A systematic review of stakeholder perspectives.PloS one · 2021Pooled it
- Tele-Genetic Versus Onsite Counseling for APOE Disclosure: A 6-Month Study of Empowerment, Psychological Distress, and Behavioral Outcomes in Cognitively Diverse Individuals.The journal of gene medicine · 2025Trial
- Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression.Journal of genetic counseling · 2022Trial
- Predictors of extreme future time perspective change in persons who learn an Alzheimer's disease biomarker test result.Aging & mental health · 2026Article
- Now is the time: the need to update guidance to expand access toFrontiers in dementia · 2026Article
- Toward a person-centered return of research results of dementia risk: A pluralistic, constructive expansion.Journal of Alzheimer's disease : JAD · 2025Article
- Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Psychological outcomes of dementia risk estimation in MCI patients: Results from the PreDADQoL project.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice.Neurology. Clinical practice · 2024Article
- Mapping the genetic landscape of early-onset Alzheimer's disease in a cohort of 36 families.Alzheimer's research & therapy · 2022Article
- Article
- Dementia risk communication. A user manual for Brain Health Services-part 3 of 6.Alzheimer's research & therapy · 2021Review
- Behavioral and psychological impact of genome sequencing: a pilot randomized trial of primary care and cardiology patients.NPJ genomic medicine · 2021Article
- Brain health registry GenePool study: A novel approach to online genetics research.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Pilot study of an Alzheimer's disease risk assessment program in a primary care setting.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
- Polygenic Score Models for Alzheimer's Disease: From Research to Clinical Applications.Frontiers in neuroscience · 2021Review
- Grey Matter Loss at Different Stages of Cognitive Decline: A Role for the Thalamus in Developing Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2021Article
- Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment.Alzheimer's & dementia (New York, N. Y.) · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 1 country.
Funding
Abstract
introductionThe safety of predicting conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia using apolipoprotein E (
methodsWe randomized 114 individuals with MCI to receive estimates of 3-year risk of conversion to AD dementia informed by
resultsUpper confidence limits for randomization arm differences were 2.3 on the State Trait Anxiety Index and 0.5 on the Geriatric Depression Scale, below non-inferiority margins of 3.3 and 1.0. Moreover, mean scores were lower in the disclosure arm than non-disclosure arm for test-related positive impact (difference: -1.9, indicating more positive feelings) and AD concern (difference: -0.3). DISCUSSION: Providing genetic information to individuals with MCI about imminent risk for AD does not increase risks of anxiety or depression and may provide psychological benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.